Guil·lain-Bar·ré Syndrome

(gē-yăn′bə-rā′)

A temporary inflammation of the nerves, causing pain, weakness, and paralysis in the extremities and often progressing to the chest and face. It typically occurs after recovery from a viral infection or, in rare cases, following immunization for influenza.

[After Georges Guillain (1876-1961) and Jean Alexandre , Barré (1880-1967), French neurologists.]

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

Guillain-Barré syndrome

(French ˌɡije ˈbareɪ)

(Pathology) an acute neurological disorder, usually following a virus or bacterial infection, that causes progressive muscle weakness and partial paralysis

[C20: named after Georges Guillain (1876–1961) and Jean Alexandre Barré (1880–1967), French neurologists]

Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

ThesaurusAntonymsRelated WordsSynonymsLegend:

Noun

Guillain-Barre syndrome - a form of peripheral polyneuritis characterized by pain and weakness and sometimes paralysis of the limbs; cause is unknown

infectious polyneuritis, Landry's paralysis

multiple neuritis, polyneuritis - inflammation of many or all of the peripheral nerves (as in leprosy)

Translations

Guil·lain-Bar·ré syn·drome

n. Guillan-Barré, síndrome de, enfermedad neurológica rara que se evidencia por parálisis ascendente que comienza por las extremidades y puede llegar rápidamente a los músculos respiratorios en dos o tres semanas causando fallo respiratorio.

English-Spanish Medical Dictionary © Farlex 2012

Mentioned in

References in periodicals archive

By Applications : Chronic Inflammatory Demyelinating, Hypogammaglobulinemia Multifocal Motor Neuropathy, Immunodeficiency Diseases, CVID (common variable immunodeficiency), SCI (severe combined immunodeficiency), Primary Humoral Immunodeficiency, Unknown (idiopathic) Immunodeficiency diseases, Myasthenia Gravis, Guillain-Barre syndrome, MFS (Miller Fisher Syndrome), AMAN (Acute motor axonal neuropathy) and AMSAN (acute motor-sensory axonal neuropathy), Kawasaki disease, and ITP among others.

Intravenous Immunoglobulin (IVIg) with Top Companies Overview, Current Trends, Growth Key Drivers, Investment Feasibility, Enhancements and Global Development till 2023

It includes AIDP, AMAN, acute motor-sensory axonal neuropathy (AMSAN), Miller Fisher syndrome, acute panautonomic neuropathy and acute sensory neuropathy, and other subtypes.

Guillain-Barre Syndrome Complicated on Postoperation on Renal Carcinoma and Meningioma

Miller Fisher syndrome (MFS) is a variant of GBS and its clinical triad includes ophthalmoplegia, ataxia and areflexia.

Acute Ophthalmoplegia; Same Disease, Different Variants: Anti GQ1b Antibody Syndrome

acute bulbar palsy (ABP) with no limb weakness, differentiating it from the Miller Fisher syndrome (MFS) and PCB2.

PHARYNGEAL CERVICAL BRACHIAL VARIANT OF GUILLAIN BARRE SYNDROME REQUIRING PROLONGED VENTILATORY SUPPORT

Miller Fisher syndrome: A case report highlighting heterogeneity of clinical features and focused differential diagnosis.

Miller Fisher-Guillain-Barre overlap syndrome during the Zika Virus outbreak

History, clinical examination and investigation findings were suggestive of Miller Fisher Syndrome and treatments started with 5 cycle of Plasmapheresis, which were given over a period of 15 days.

An uncommon presentation of miller fisher syndrome

Miller Fisher syndrome: a case pattern of pure sensory polyneuropathy concomitant with anti- GQ1B antibody.

Miller-Fisher Syndrome: a case report/Miller-Fisher Sendromu: olgu sunumu

Miller Fisher syndrome: brief overview and update with a focus on electrophysiological findings.

An 85-year-old woman with Miller Fisher syndrome

(2005) Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann.

Guillain-Barre syndrome and anti-ganglioside antibodies: a clinician-scientist's journey